DLA
BIIB icon

Douglas Lane & Associates’s Biogen BIIB Stock Holding History

Douglas Lane & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-616
Closed -$213K – 226
2021
Q2 		$213K Buy
+616
New +$187K ﹤0.01% 220
2019
Q1 		– Sell
-726
Closed -$218K – 218
2018
Q4 		$218K Hold
726
– – 0.01% 196
2018
Q3 		$257K Buy
+726
New +$250K 0.01% 187
2018
Q2 		– Sell
-824
Closed -$226K – 196
2018
Q1 		$226K Sell
824
-50
-6% -$15.5K ﹤0.01% 188
2017
Q4 		$278K Buy
874
+20
+2% +$6.42K 0.01% 182
2017
Q3 		$267K Sell
854
-15
-2% -$4.44K 0.01% 188
2017
Q2 		$236K Buy
869
+65
+8% +$17.2K 0.01% 192
2017
Q1 		$220K Sell
804
-197
-20% -$55.7K 0.01% 198
2016
Q4 		$284K Sell
1,001
-300
-23% -$88.9K 0.01% 192
2016
Q3 		$407K Sell
1,301
-95
-7% -$28.1K 0.01% 180
2016
Q2 		$338K Buy
1,396
+36
+3% +$9.49K 0.01% 189
2016
Q1 		$354K Buy
+1,360
New +$359K 0.01% 186

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Douglas Lane & Associates's BIIB Position: Q3 2021 in Review

Douglas Lane & Associates sold out of Biogen (BIIB) in Q3 2021, closing a stake of 616 shares — an estimated $213K sold.

Douglas Lane & Associates first reported a position in BIIB in Q1 2016 and held it in 12 quarters. The position peaked at $407K in Q3 2016. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

  • Douglas Lane & Associates reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
  • Douglas Lane & Associates sold 616 Biogen shares in Q3 2021, an estimated $213K.
  • Douglas Lane & Associates first reported a position in Biogen in Q1 2016 and held it in 12 quarters.
  • Douglas Lane & Associates's Biogen position peaked at $407K in Q3 2016.
  • 1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Douglas Lane & Associates's 13F filing for Q3 2021, filed 21 Oct 2021.